Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.
Baxter A, Brough S, Cooper A, Floettmann E, Foster S, Harding C, Kettle J, McInally T, Martin C, Mobbs M, Needham M, Newham P, Paine S, St-Gallay S, Salter S, Unitt J, Xue Y.
Baxter A, et al.
Bioorg Med Chem Lett. 2004 Jun 7;14(11):2817-22. doi: 10.1016/j.bmcl.2004.03.058.
Bioorg Med Chem Lett. 2004.
PMID: 15125939